Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fazamorexant Phase 2 in Primary Chronic Insomnia
NCT06680505Phase 2Completed
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
- Start
- Aug 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fazamorexant in chronic insomnia disorder (CID), sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Primary endpoint: Sleep Efficiency at Day 28. Started Aug 2019; status: completed.
02
Drugs
fazamorexant
03
Conditions
chronic insomnia disorder (CID)
Beyond the preview
Go deeper on NCT06680505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06680505.